in the concentration-response curve of the full agonist without a reduction of the maximum response, suggesting that the full agonist has spare receptors ( Fig. 1) (1-3). A fractional effect is then equal to the product of fractional occupancy of the receptor and the fractional efficacy. These correction factors are dependent both on the molecular properties of receptors and on the concentra tions of agonists and interactions of transducer and effec tor proteins.
Presented here is an overview of the modification of the classical drug receptor mechanisms by investigating the mechanisms of the two subtypes of both M3-cholino ceptor and al-adrenoceptor that are discriminated by the ,3-chloroethylamines: propylbenzilylcholine mustard (PrBCM, N-2 chloroethyl-N-propyl-2-aminoethyl benzyl ate) or chloroethylclonidine (CEC). The longitudinal smooth muscle of guinea pig ileum and the guinea pig taenia caecum are contracted by M3 receptor activation (4) . Carbachol , butyltrimethylammonium ( Fig. 2) , pro pionylcholine and butyrylcholine behaved as full agonists on M3-receptors in the longitudinal muscle of guinea pig ileum. They were progressively inhibited by 10 to 50-min treatment with PrBCM (3 x 10-6 M), and the results were in good agreement with those obtained with guinea pig taenia caecum (5, 6) . The 50-min treatment of the lon gitudinal muscle strip with PrBCM irreversibly inhibited the concentration-response curves of the full agonists. These facts confirmed the results of Young et al. (7) who reported that PrBCM irreversibly antagonized the con tractile response of the intestinal muscle to muscarinic agonists. More prolonged (90 min) treatment with PrBCM had no further significant inhibitory effect on the concentration-response curves of full agonists (Fig. 2) . The results suggest that there are two subtypes of M3 cholinoceptors, PrBCM-sensitive and -resistant cholino ceptors.
Pilocarpine, heptyltrimethylammonium, benzoylcho line ( Fig. 3) , hexyltrimethylammonium, pentanoylcholine and hexanoylcholine acted as partial agonists. Their con centration-response curves were completely inhibited by the 50-min treatment with PrBCM.
The full agonists elicit a stimulus through an interac tion of two subtypes of M3-cholinoceptors, as the limiting inhibitory effect of PrBCM was observed on the concen tration-response curves of the full agonists. The response to the partial agonists disappeared as a result of the 50-min treatment with PrBCM. These facts suggest that the partial agonists produce contraction by activating PrBCM-sensitive cholinoceptors. However, the fact that in the strips treated with PrBCM, pilocarpine shifted the concentration-response curve of carbachol in a parallel fashion suggests that the interaction of pilocarpine with PrBCM-resistant receptors does not induce contraction but acts as a muscarinic antagonist (Fig. 4) . The full agonists contract the intestinal smooth muscle through the interaction of two cholinoceptors, PrBCM-sensitive and -resistant ones, while the partial agonists produce the contraction through the activation of the PrBCM-sensi tive ones (Fig. 5) (8) . Dorje et al. (9) determined the affinity profiles of sev eral selective muscarinic antagonists at five cloned human muscarinic receptors (ml-m5) stably expressed in Chinese hamster ovary cells (CHO-K 1). At least four sub types of muscarinic receptors were pharmacologically characterized and are designated as M1, M2, M3 and M4 according to their affinity for selective antagonists (4, (10) (11) (12) . Comparison of the location, antagonist binding properties and functional coupling of the native muscarinic M1-M4 receptors with those of the expressed ml-m4 proteins showed a good correlation. Therefore, the subtype of PrBCM-sensitive and -resistant muscarinic cholinoceptors in the longitudinal smooth muscle of guinea pig ileum was examined using four selective muscarinic antagonists: pirenzepine (M1 [ml] selective) (13) . Receptors unmarked and marked with P: PrBCM-resistant and PrBCM-sensitive cholinoceptors, respectively. The full agonist interacts with both PrBCM-sensitive and PrBCM-resistant cholinoceptors to induce contraction. However, the partial agonist induces contraction through the interaction with PrBCM-sensitive receptors, but acts as an antagonist of the full agonist on PrBCM-resistant ones.
Concentration-response curves of carbachol after a 50-min treatment with PrBCM and those of pilocarpine without PrBCM-treatment were shifted to the right in a parallel manner by each of the four antagonists. The pA2 values and slopes of the four antagonists are shown in Table 1 . Schild plots of these results yielded a straight line with a slope of 1 ( Table 1 ). The pA2 values of the four antagonists against pilocarpine did not differ from their values against carbachol after the treatment with PrBCM (Table 1 ) and were identified with the values for the M3-subtype. These results suggest that the subtype of PrBCM-sensitive and -resistant muscarinic cholino ceptors in the longitudinal smooth muscle of guinea pig ileum is the M3-subtype (17). Two different subtypes of M3-cholinoceptors were identified in the intestinal smooth muscles using PrBCM: one PrBCM-sensitive and the other PrBCM-resistant.
Furthermore, the left atrium of guinea pig, driven electrically, was used as a test organ containing M2 cholinoceptors. Concentration-response curves of car bachol and butyltrimethylammonium, muscarinic full agonists, were progressively inhibited by 10 and 30-min treatments with PrBCM (10-6 M). The 50-min treatment had no further significant inhibitory effect on their curves, while the 30-min treatment completely inhibited the concentration-response curve of pilocarpine, a partial agonist. In the atrium after the 30-min treatment with PrBCM, pilocarpine shifted the concentration-response curves of the full agonists, suggesting a competitive antagonism. These results suggest the existence of two subtypes of M2-receptors, PrBCM-sensitive and -resistant ones, and also suggest that the full agonists inhibit the twitch through interaction of these two subtypes, while the partial agonist produces inhibition through an acti vation of the PrBCM-sensitive ones (18). These findings are similar to the difference in full and partial agonist cholinoceptor mechanisms on M3-receptor in the intesti nal smooth muscle of guinea pig (Fig. 5) . PrBCM was reported to be selective for some populations of rat heart muscarinic cholinoceptors (19). It was also reported that PrBCM could not completely inactivate [3H]quinuclidinyl benzilate (QNB) binding sites in the guinea pig heart. Nonlinear regression analyses revealed that carbachol binds to three different affinity sites: the super-high (SH), high (H) and low (L) subsites (Table 2) in membranes obtained from guinea pig taenia caecum, as reported in a variety of tissues (30-34). The pIC50 value (the negative logarithm of the 50% inhibitory concentration estimated from its displacement curve) for carbachol was decreased, but that for atropine was not, by in vivo alkylation of the muscle strips with PrBCM for 50 min, a condition under which only the PrBCM-resistant sites remained. The loss in the affinity of carbachol in the PrBCM-pretreated membranes could not be explained by a selective inacti vation of the SH and/or H subsites by the in vivo alkyla tion, because if such higher affinity subsites which ac counted for about 90010 of the total receptor sites were destroyed by PrBCM, the PrBCM-resistant receptor would essentially be occupied only by the L subsite. Ac tually, SH, H and L subsites also coexist in the PrBCM resistant sites; consequently, the apparent decrease in affinity of carbachol to the receptor sites was revealed to be due to both the relative abundance of the H and L subsites and the relative scarcity of the SH subsite in the PrBCM-resistant receptors. The difference in the relative density of each subsite between the PrBCM-sensitive and -resistant sites seems to further support the distinct entities or states of both receptor sites.
It is well-known that the guanine nucleotides lowers the affinity of agonists but not antagonists to many types of receptor systems including muscarinic receptors via inter action of the receptor with G proteins. The decrease in the affinity of carbachol, but not of atropine, by in vivo alkylation is apparently not due to a mechanism by which PrBCM might act on the receptor systems to convert them to a state similar to that in the presence of the guanine nucleotide, since guanosine 5'-O-(3-thiotriphos phate) (GTPiS) was able to further decrease the affinity of carbachol in membranes from the PrBCM-pretreated muscles, as in the control membranes. The shift of the pIC50 value by GTP1S in the PrBCM-resistant receptor sites suggests that these sites may couple with G proteins to induce a PrBCM-resistant contraction.
To investigate the mode of interaction of PrBCM with the two receptor sites, the binding characteristics were studied in the membrane fractions from muscle strips that had been pretreated with PrBCM (in vitro alkylation) followed by centrifugal washes to remove the alkylating drug. Interestingly, by this in vitro alkylation method, the pIC50 values for carbachol were not changed. In view of the results obtained with the in vivo alkylation method, some missing cytoplasmic factor must be responsible for the selective inactivation by PrBCM of the receptor sites for the drug. Table 2 . The pIC5o values and the pK; values for carbachol at super-high (SH)-, high (H) and low (L)-affinity subsites with their relative densities in the membranes prepared from control and alkylated guinea pig taenia caecum and the effects of 3 mM GTP on these parameters
Tissue-alkylation was carried out by incubation of the muscle strips with PrBCM (3 x 10-' M) for 50 min, and membrane-alkylation was carried out by incubation of the membranes with PrBCM (10-8 M) for 30 min. *Significantly different from the corresponding values in the control at P<0.05. Fig. 6 . Structures of propylbenzilylcholine mustard (PrBCM), its aziridinium ion and alcoholic hydrolysis product and benactyzine.
Our study showed that GTP may be one of the candi dates for such a cytoplasmic factor and that GTP1S makes some populations of the receptor sites resistant to PrBCM. First, the guanine nucleotide reduced the amount of [3H]PrBCM specifically bound to the mem branes by about 15070. Although somewhat larger, the value was comparable to the relative density of the PrBCM-resistant sites revealed by Scatchard analyses of
[3H]QNB binding sites in the in vivo alkylated mem branes. Secondly, simultaneous incubation of mem branes with GTP during the in vitro alkylation by PrBCM decreased the pIC50 value for carbachol, as observed in in vivo alkylated membranes (GTP1S was not used in this experiment, because the binding of GTP to G proteins is almost irreversible). When membranes were preincubated with GTP alone followed by centrifugal washes, the affinity of carbachol was not altered compared with the control value. Thus, the decrease in the affinity of car bachol by in vitro alkylation in the presence of GTP is considered not to be induced via a so-called GTP-shift by the contaminating GTP in the washed membranes due to incomplete removal of the nucleotide (Table 2) .
Taken together, the present results suggest that in guinea pig taenia caecum, there coexist two types of mus carinic receptor mechanisms, although it is currently unknown whether the difference in sensitivity of the two sites to PrBCM is due to the distinct entities of the recep tor molecules, the same receptor with different modifica tions or as yet undefined mechanisms. PrBCM can differ entiate between the two mechanisms, PrBCM-sensitive and -resistant ones, in the presence of GTP, but in its absence, PrBCM cannot discern the two. In other words, one mechanism is PrBCM-sensitive, irrespective of the presence or absence of GTP, and the other is PrBCM resistant only when GTP is present (29).
PrBCM discriminates between PrBCM-sensitive and -resistant M3-cholinoceptors, as described above. One reason for this fact may be that the benzilylcholine moiety in PrBCM discriminates the two subtypes. We tested the effects of benactyzine ( 
PrBCM
cyclizes spontaneously into quaternary aziridinium ion in aqueous solution at neutral pH, and aziridinium ion alters further into an alcoholic hydrolysis product (Fig. 6 ). There are PrBCM and its aziridinium and alcoholic hydrolysis product in aqueous solution.
Quaternary aziridinium ion is believed to have the highest affinity for cholinoceptor among these three. Aziridinium ion interacts with anionic groups in receptors and binds covalently with a certain portion of the receptors. Thus, PrBCM blocks receptors irreversibly. Young et al. (7) reported that 84.5% of PrBCM exists as aziridinium ion in 8 x 10-4 M PrBCM phosphate buffer (pH 7.5), kept at 32'C for 20 min. A small amount of this solution was added to bath fluid, a final aziridinium ion concentration of about 10-' M, although the exact concentration in the diluted fluid was unknown. Bath fluid does, however, contain aziridinium ion, alcoholic hydrolysis product and PrBCM; in this paper, the bath fluid containing aziridin ium and other components is referred to as aziridinium ion solution. To test the interaction of aziridinium ion with PrBCM-sensitive and -resistant receptors, the prepa ration was treated with aziridinium ion solution for 3 min. In the untreated longitudinal muscle of guinea pig ileum, the concentration-response curve of pilocarpine was depressed by this ion solution. Although the ileal preparation was allowed to equilibrate for 60 min with washing every 10 min, the curve of pilocarpine was not significantly influenced. These results suggest that the 3-min treatment with aziridinium ion solution blocks PrBCM-sensitive receptors (Fig. 7A) . In the PrBCM treated ileal longitudinal muscle, the concentration response curve of carbachol was reduced by the 3-min treatment with the solution. The response to carbachol returned to one like the control after the preparation was allowed to equilibrate for 60 min with washing every 10 min (Fig. 7B) ; this indicates that depression of the response to carbachol by aziridinium ion solution is due to an ionic interaction of PrBCM-resistant receptor with aziridinium ion but not to alkylation. As indicated in the relationship between log carbachol concentration and logit, log (Y / (Yma~, Y)) (inset of Fig. 7B ), where Y is the response to carbachol and Ymax is the maximum response in the absence or presence of aziridinium ion solution, the curve of carbachol was shifted by the solution in a parallel fashion, suggesting that aziridinium ion competes with carbachol for PrBCM-resistant cholinoceptors (I. Takayanagi et al., unpublished data). It is generally accepted that a compound with bulky groups acts as a competitive and non-competitive antagonist (35). Aziridinium ion and alcoholic hydrolysis product have bulky groups, whereas benactyzine does not. Benactyzine acts as a pure competitive antagonist, while aziridinium ion and alcoholic hydrolysis product may behave as com petitive and non-competitive antagonist, respectively. These results open the following possibilities: PrBCM, which contains benzilylcholine moiety in its molecule, has higher affinity to PrBCM-sensitive receptor than to PrBCM-resistant receptor, and it is able to bind co valently with the former but not with the latter.
It is difficult to explain why PrBCM does not bind covalently with PrBCM-resistant receptors. PrBCM may interact with both possible subtypes of M3-cholinoceptors in the absence of GTP, that is to say, PrBCM does not discriminate between PrBCM-sensitive and -resistant receptors without GTP (29). However, GTP converts some populations of PrBCM-sensitive receptors to resistant receptors. Thus, PrBCM discriminates between the two subtypes only in the presence of GTP. And thus, the conformation of PrBCM-resistant receptors in the presence of GTP may be suitable to interact with aziridinium ion but not to bind covalently. The rabbit thoracic aorta and common iliac artery contain both alA and a1B-adrenoceptors. Based on the affinity for WB4101 [2-(2,6-dimethoxyphenoxyethyl) aminomethyl-1,4-benzodioxane] and susceptibility to CEC, the subtypes of al-adrenoceptors activated by phenylephrine (a full agonist) and tizanidine (a partial agonist) were evaluated. The a1 -subtype has a high affinity for WB4101, while the alB-subtype has a low affinity and is selectively susceptible to CEC (an alB adrenoceptor-alkylating agent) (36). CEC partly inhibited the concentration-response curves of phenylephrine, a full agonist in both rabbit common iliac artery and thoracic aorta, suggesting that the con tractile response to the full agonist was at least partly mediated through a,B-adrenoceptors. However, the alB adrenoceptors are thought to be more prevalent in the common iliac artery than in the thoracic aorta, since CEC more effectively inhibited the responses to the agonist in the common iliac artery than in the thoracic aorta. The curve of tizanidine, a partial agonist, was not significantly influenced by CEC, however. In the thoracic aorta, the slope of the Schild plot obtained from an antagonism be tween tizanidine and WB4101 was equal to 1, while the slope of the plot from the antagonism between phenyl ephrine and WB4101 was significantly less than 1. Two pA2 values for WB4101 were estimated from the antago nism between phenylephrine and WB4101 in rabbit thoracic aorta, suggesting that WB4101 interacts with two distinct receptors (Fig. 8) . According to computer-assist ed analysis of the nonlinear Schild plot for WB4101 and the a,-adrenoceptor stimulant in rabbit aorta (37), the high-affinity site for WB4101 obtained herein is the alA subtype and the low-affinity site, the ale-subtype (Fig. 8) .
These results suggest that the rabbit thoracic aorta contains the alB-subtype in addition to the a,A-subtype. Phenylephrine, a full agonist, induced contraction through both subtypes and the contractile response to tizanidine, a partial agonist, mainly through the alA-sub type (38).
Moreover, using norepinephrine, a full agonist, and clonidine, a partial agonist, the similar results were ob tained (39). The results confirmed that a full agonist in duced contraction through both a,A and a,B-subtypes, and a partial agonist induced it through only the alA-sub type (Fig. 9) . 11-2-2. Effects of guanine nucleotide a,-Adrenoceptors in membrane prepared from rabbit thoracic aorta were selectively labeled with [3H]prazosin, and then the labeled receptors were displaced by the a, agonist phenylephrine. The computer analysis of the dis placement curve showed the presence of high-affinity and low-affinity sites (Table 3) .
Although the low-affinity site was reduced by the pretreatment of tissues with CEC, this site was unaffected by the same pretreatment of membrane preparations that did not contain the metabolically stable GTP analog GTPrS. However, in membrane preparations where GTPrS was added and single cell preparations where there was endogeneous GTP, the low-affinity site was completely eliminated by the CEC pretreatment. Dis placement studies with the al-antagonist WB4101 also revealed high and low-affinity binding sites labeled by
[3H]prazosin. Displacement curves of WB4101 obtained from membrane preparations in the presence of GTPrS did not differ from those in the absence of GTPrS. These results suggest that the low-affinity site of phenylephrine binding labeled with [3H]prazosin was selectively bound by CEC which was used to pretreat the tissues, membrane preparation containing GTPrS and single cells. GTPrS may convert a conformation of a1B-adrenoceptors that is suitable to interact with CEC and then bind covalently with them. Thus, CEC is able to recognize these two distinct subtypes of al-adrenoceptors only when GTPrS is present (40). CEC, like PrBCM, cyclizes spontaneously into quarternary aziridinium ion in aqueous solution and then changes into an alcoholic hydrolysis product. Aziridinium ion is thought to interact with anionic groups in a1B-adrenoceptors to bind covalently with them. To test interactions of aziridinium ion with alA (CEC resistant) and a1B (CEC-sensitive)-receptors, the prepa rations were treated with CEC (10-4 M) for 3 min. Rabbit iris dilator muscle was used as an a1B-adrenoceptor predominant preparation and rabbit aorta muscle where a1B-adrenoceptors were almost completely blocked by the 60-min treatment with CEC (10-'M) as an atA adrenoceptor-predominant one. Concentration-response curves of norepinephrine obtained in the two prepara tions were shifted in parallel by the 3-min treatment with CEC (10-4 M) (Fig. 10) , suggesting that aziridinium ion interacts with both alA and a1B-adrenoceptors (I. Takayanagi et al., unpublished data). After these interac tions, aziridinium ion binds covalently with a1B-receptors but not with alA-receptors. for pilocarpine that only interacts with PrBCM-sensitive ones. The slope for pilocarpine was sig nificantly steeper than that for carbachol. These results suggest that greater tension is induced for a given increase in [Ca 21], in the presence of pilocarpine, which activates PrBCM-sensitive receptors, than in the presence of car bachol, which activates PrBCM-resistant ones. It is well known that contraction of smooth muscles is regulated not only by [Ca 2+]i but also by the Ca2+-sensitivity of the contractile elements (42-45). In the guinea pig intestinal smooth muscle, pilocarpine was a partial agonist with high intrinsic activity in a normal physiological solution, while it behaved as a partial agonist with lower intrinsic activity in the solution from which Ca2+ was removed. Also, carbachol has a higher inositol-triphosphate formation capacity than pilocarpine (46). Konno and Takayanagi (46) concluded that carbachol, a full agonist, was apparently able to mobilize stored Ca 2+ better than pilocarpine. Consequently, the contractile response to pilocarpine is more dependent on Ca2+-influx than is the response to carbachol. They (46) also reported that pilocarpine was a partial agonist with lower intrinsic activity in phosphatidylinositol turnover. Taking the aforementioned observations into account (46), the present results suggest that the activation of PrBCM sensitive receptors might enhance the Ca" -sensitivity of the contractile elements (47 49). Secondly, fura 2-loaded thoracic aorta strips from rab bits were used. Norepinephrine, phenylephrine, clonidine and tizanidine induced an increase in [Ca 2+] and muscle tension in a concentration-dependent manner. A positive correlation between [Ca 2+]i and tension development owing to the agonists was noted (Fig. 12) . The slope of regression lines between [Ca 2+]i and tension development for clonidine and tizanidine, a,-adrenergic partial agonists, were significantly steeper than those for norepi nephrine and phenylephrine, a,-adrenergic full agonists. The intrinsic activities of the partial agonists obtained from tension development were greater than those from changes in [Ca 2+]i. Furthermore, the slopes of the regres sion lines between [Ca 2+]i and tension development for both the full agonists in the CEC-treated preparations, which did not contain a,B-adrenoceptors, were signifi cantly steeper than those in the untreated ones, which contained both a,A and alB-adrenoceptors. These results suggest that the partial agonists, a,A-adrenoceptor activa tors, cause a greater muscle tension than the full agonists, a,A and a,B-adrenoceptor activators, at the same level of [Ca 2+j, (50, 51). Receptor stimulations evoked by agonists produce vari ous signal transducing substances in smooth muscle cells and thereby activate the contractile apparatus. As we have mentioned in Section III, the observed Ca 21 -tension relationship produced by full and partial agonist suggests the presence of an additional regulatory mechanism that modulates the Ca2+-sensitivity of contractile elements: MLC-phosphorylation-dependent and -independent path ways, which are regulated by protein kinase Cs (PKCs) stimulated by phorbol esters (53) or low molecular weight GTP binding protein families (54-56).
Adrenoceptors and cholinoceptors belong to the family of seven transmembrane segment receptors, which are heterotrimeric (a~r) G protein-coupled to phospho inositide-phospholipase C, and cause a rapid hydrolysis of inositol phospholipids, resulting in the generation of two second messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (57). The former releases Ca 21 from the cellular storage sites and activate Ca 21 /calmodulin-dependent kinases including PKC, with the subsequent phosphorylation of MLC and the initiation of contraction. DAG is the endogenous activator of PKC, a serine/threonine kinase that plays an important role in signal transduction during contractile responses (58, 59). In vascular (60-62) and tracheal (63) smooth muscle, there is substantial evidence indicating that PKC activa tion is involved in increased myofilamental Ca 2+-sensi tivity. Pharmacological procedures have provided data showing that PKC induced contraction requires less Ca 21 than those elicited by membrane depolarization, enabling us to see an important role for PKC in the regu lation of smooth muscle contraction. On the other hand, in addition to the increase in intracellular Ca2+ concen tration released from Ca 24 storages, receptor stimulation evoked Ca2+-influx from extracellular fluid through volt age-dependent and/or receptor-operated Ca2+ channels.
The existence of a link between the phospholipase C pathway and Ca2+ channels (64) and the existence of two pharmacologically distinct receptor subtypes that couple with a different Ca 2+ signalling mechanism and having different physiological roles were propounded (37). We already described that the partial agonists cause greater muscle tension than the full agonists at the same level of [Ca 2+]; (Figs. 11 and 12) . Therefore, in rabbit aorta and guinea pig ileum, which contain two receptor subtypes, the final physiological contractile responses is considered to be caused by the intracellular communication be tween at least two pathways. In j3-escin skinned vascular smooth muscle of rabbit thoracic aorta, Ca2+-sensitivity of the contraction in duced by constant cytoplasmic Ca" of 3 x 10-7 M (pCa 6.5) was increased through both a,A and aiB-subtypes activated by norepinephrine (10-5 M), but through only the alA-subtype activated by methoxamine (10-'M) or clonidine (10-4 M) (38). With alB-adrenoceptor-alkyl ating agent CEC-pretreated tissue, the Ca 2+-sensitization produced by norepinephrine was similar to that produced by methoxamine and clonidine, which was not affected by the CEC-pretreatment.
In the presence of GTP or GTP1S, the Ca2+-sensitization of Ca2+-evoked contrac tion produced by a,-adrenoceptor agonists and that through the a,A-subtype is inhibited by the PKC inhibi tor, H-7 [1-(5-isoquinolinylsulfonyl)-methyl-piperazine]. The activators of PKC, phorbol esters, showed effects similar to those of agonists in that they increased the Ca2+-sensitivity of MLC-phosphorylation (60, 65) and activated a mechanism that is independent on MLC phosphorylation (66), being supported by the observation that the potent MLCK inhibitor KT5926 [(8R*,9S*,11S*) (-)-9-hydroxy-9-methoxycarbonyl-8-methyl-(14-n-pro poxy-2,3,9,10-8,11-epoxy,1H, 8H,11H,-2,7b,1l a-triazadi benzo[a,g]cycloocta[cde]trinden-1-one] decreased a part of the contraction potentiated by phorbol esters (67). After the exposure of muscle strips to clonidine, there is a rapid increase in the activity of PKC in the particulate fraction (Fig. 13A, closed circles) , while the activity of PKC in cytosolic protein tended to concomitantly decrease. In the preparations with down-regulated PKC activity by the treatment with phorbol ester, the Cat+ sensitizing effects of phorbol ester were completely abolished (68, 69). Because agonists activate PKC through the formation of DAG, we can be fairly certain that PKCs, including in atypical isoforms, participate in the Cat+-sensitizing pathways activated by agonists in smooth muscle. Furthermore, the Cat+-sensitization in duced by agonist is inhibited by the pretreatment of the muscle with Clostridium botulinum C3 (C3). Earlier, Morii et al. (70) reported the existence and tissue distri bution of Gb (Rho) in aorta and suggested that this pro tein has a contractile function as shown by its wide dis tribution in the body. Low molecular weight GTP-bind ing proteins (Ras superfamily) are mainly proteins of the Ras family, Rho family and Rab family. These three families are involved in controlling a diverse set of essen tial cellular functions including proliferation, cytoskeletal organization and intracellular vesicle transport (71). As shown in Table 4 , agonist-enhanced Ca 21 -sensitivity of the skinned smooth muscle contraction is almost elimi nated by C3, and this is supported by similar observations that the GTPYS-enhanced Ca t+-sensitivity was abolished by C3 (56). By using a biochemical technique, purified C3 from the culture medium of a type C strain has been shown to ADP-ribosylate Rho on asparagine 41 (72-75); and it is concluded that Rho A p21, which belongs to the Ras p21-like low molecular weight GTP-binding protein superfamily, is involved in the Ca 21 -sensitization of smooth muscle contraction (56). The Ca 21 -sensitization through the activation produced by the al-adrenoceptor agonists clonidine and norepinephrine in the CEC-treated preparation, which shows the KT5926-resistant response, may have been mediated through GTP-binding protein coupled inhibition of MLC phosphatase in phos phorylation-dependent pathways. Though the protein phosphatases modulated by GTP-binding protein(s) remain to be identified, C3-sensitive low molecular weight GTP-binding protein(s) may be involved in the inhibi tory effect of the negative modulation of phosphatase activity (76). The activation of PKC produced by the alA-subtype stimulant clonidine was not affected by C3-treatment as shown in Fig. 13 . However, the PKC inhibitor H-7 in hibited the Cat+-sensitization produced by norepineph rine (62), and phorbol ester-induced Ca 21 -sensitization is also partly inhibited by C3 (67). These findings suggest that PKC is important in the regulation of Ca t+-sensitiv ity to the agonist-induced contractions.
Moreover, in the skinned smooth muscle treated with C3, PKC activated by clonidine had the same level of activity as PKC activated by clonidine without C3, showing no regulatory effect of PKC on C3-sensitive protein (Fig. 13) ; this indicates that PKC, which produces Ca" -sensitization in smooth mus cle, is in a position unaffected by C3-sensitive GTP-bind ing proteins: a step above, upstream from C3-sensitive GTP-binding proteins in the Ca t+-sensitizing cascade or independent of C3-sensitive GTP-binding proteins. With a1B-adrenoceptor-alkylation agent CEC-treated tissue, where only the a1 -subtype remained, the enhancement of Ca2+ contraction produced by norepinephrine was not affected by the potent MLCK inhibitor KT5926. Moreover, the amount of MLC-phosphorylation induced by 10-5 M norepinephrine was greater than that by 10-4 M clonidine (Fig. 14) , indicating that the different Ca2+ sensitizing effect of these two agonists is not related to the amount of phosphorylated MLC. Using intact aortic strips, the MLCK inhibitor KT5926 markedly inhibited the contractile response to norepinephrine (the residual response: 47.6±7.40%, n=4), but only slightly inhibited the contractile response to clonidine (the residual response: 80.6±6.25%, n=4) and that to norepineph rine in CEC-treated tissue (Fig. 15) . These results mean that norepinephrine predominantly produces the contrac tile response through phosphorylation of MLC by the activation of MLCK, whereas clonidine induces the contraction through the phosphorylation-independent pathway of MLC; this shows that the alA-adrenoceptor subtype activates the MLC-phosphorylation-independent pathway in rabbit vascular smooth muscle (77). In addi tion, K-252a [(8R *,9S*,11 S*)-(-)-9-hydroxy-9-methoxy carbonyl 8 methyl 2, 3, 9, 10 tetrahydro 8, 11 epoxy IH,8H,11H-2, 7b, 11 a-triazadibenzo [a, g] cycloocta[cde] trinden-l-one], a potent inhibitor of protein kinases, also caused similar inhibitory effects to KT5926 on the con tractile response to norepinephrine and clonidine with CEC-untreated or -treated tissues (77). These findings suggest that the contraction induced through a1 adrenoceptors is initiated by a direct mechanism, possibly phosphorylation of MLC, which is mainly activated through the a1B-adrenoceptor subtype, and that the agonists may increase the Ca2+-sensitivity of contractile elements by increasing the Ca2+-sensitivity of MLC-phos phorylation. On the other hand, although actin-binding proteins, calponin and caldesmon bind to actin and inhibit the actin-myosin interactions, this activity is abolished by Ca 2+/calmodulin (78 80). The dissociation of these proteins from actin-filaments results in the Ca2+ sensitization of muscle contraction. alA-Adrenoceptors stimulated by clonidine activate the actin-myosin inter actions through an actin regulating protein such as calponin or caldesmon on the grounds that the amount of MLC-phosphorylation and inhibitory effects of MLCK inhibitor on clonidine-induced contraction is smaller than those on the norepinephrine-induced one. Both a1 adrenoceptor subtypes (a1A and a1B) increase the Ca2+ sensitivity of contractile elements. The Ca2+-sensitization produced by alA-subtype receptors is mainly caused by the MLC-phosphorylation-independent pathway medi ated through PKC and low molecular weight GTP-binding protein (Rho A p21), and that produced by a113-subtype receptors is mainly caused by the MLC-phosphorylation dependent on Ca 21 (Fig. 16) (81) . (Fig. 18: A, B and C). As shown in Fig. 11 , Ca2+ contraction was increased more effectively in the presence of pilocarpine than in the presence of carbachol. These results confirmed the find ings that in the fura 2-loaded intestinal smooth muscle of guinea pig, pilocarpine induces greater contraction than carbachol at the same level of [Ca 2+];. As the Ca 2+-sen sitization in various smooth muscles is accompanied by an activation of PKC (62, 67, 82-84) in the a-toxin skinned ileal smooth muscle of guinea pig, all the PKC inhibitors used partly inhibited contraction induced by Ca2+ in the presence of pilocarpine, and the following application of the MLCK inhibitor wortmannin com pletely inhibited the residual Ca 2+-contraction to the rest ing level (Fig. 18: A, B and C) . The Ca 21 -sensitization enhanced by pilocarpine is partly related to PKC and also to MLC-phosphorylation.
In addition, the inhibitory effect of calphostin C, a PKC inhibitor, on the Cat+ induced contraction of the botulinum ADP-ribosyltrans ferase C3-treated preparation (Fig. 18D ) was significantly smaller than that on the untreated one (Fig. 18A) , indi cating that the low molecular weight GTP-binding pro tein (Rho) is also involved in the Ca 2+ -sensitization enhanced by pilocarpine (I. Takayanagi et al., unpub lished data). Itagaki et al. (85) also suggested the involve ment of a Rho p21-like low molecular weight GTP-bind ing protein in the regulation of Cat+-sensitivity using ẽ scin-skinned smooth muscle of guinea pig ileum. It is possible that Rho p21 is involved in the Cat-sensitiza tion of smooth muscle contraction mediated by PrBCM sensitive M3-cholinoceptor. The concentration-response curve of pilocarpine in the untreated preparation or of carbachol in the PrBCM treated preparation, either of which contains only PrBCM-resistant cholinoceptor, was clearly reduced by the Cat+-antagonist nicardipine (3 x 10-9 and 10-8 M) in a non-competitive fashion. The negative logarithm of the nicardipine concentration reducing the maximum re sponse to agonist to one half the maximum response was obtained. The value obtained from the antagonism against pilocarpine was 8.25 -±:0.03 and that against car bachol was 8.22±0.03. These two values are not sig nificantly different, suggesting that Ca2+-influxes through activation of PrBCM-sensitive and -resistant receptors were equally inhibited by nicardipine and that the con tractions through both subtypes are mainly through Ca2+-influxes (I. Takayanagi et al., unpublished data). Konno and Takayanagi (46) reported that carbachol was apparently able to mobilize intracellularly stored Ca 2+ more greatly than pilocarpine. Therefore, an MLC kinase inhibitor KT5926 inhibited the contractile response of the PrBCM-treated preparation to carbachol more than that of the untreated preparation to pilocarpine (Fig. 19) , although the phosphorylation of MLC produced by carbachol was not significantly different from that by pilocarpine (I. Takayanagi et al., unpublished data). Concentrations of carbachol (10-7 M) and pilocarpine (10-6 M) used herein were equipotent. Wortmannin, another MLCK inhibitor, induced simi lar effects. In PrBCM-treated strips, it inhibited the con tractile response to carbachol (the residual response: 55.6::L6.7%, n=4), but only slightly inhibited the con tractile response to pilocarpine (the residual response: 71.4±1.01%, n=4). The above-mentioned results sug gest that both M3-cholinoceptor subtypes (PrBCM-sen sitive and PrBCM-resistant) also increase the Ca"-sen sitivity of contractile elements and suggest that the Ca2+ sensitization produced by PrBCM-sensitive subtype receptors is mainly caused by the MLC-phosphorylation independent pathway mediated through PKC and low molecular weight GTP-binding protein, whereas the Ca2+-sensitization produced by the PrBCM-resistant sub type is mainly caused by Ca 21 through the MLC-phos phorylation-dependent pathway. Based on these results, we would propose the following hypothetical system of second messengers, intracellular transducing mechanisms and pathways in smooth muscle contraction: Stimulation by agonists induces the activa tion of phospholipase C mediated through the hetero trimeric G protein and produces inositol phosphates that release Ca2+ from intracellular Ca2+ stores and DAG that activates PKC. The PKC activates low molecular weight GTP-binding protein(s) linked to actin-binding proteins, calponin and/or caldesmon. The receptor stimulations through alA-adrenoceptor and PrBCM-sensitive M3 cholinoceptor subtypes mainly activate the MLC-phos phorylation-independent pathway mediated through PKC and low molecular weight GTP-binding protein at low concentration of intracellular Ca2+ and produce efficiently sustained smooth muscle contraction, whereas the stimulations through a1B-adrenoceptor and PrBCM resistant M3-cholinoceptor subtypes activate the MLC phosphorylation-dependent pathway directly related to Ca 2+/calmodulin (Fig. 16) (81) .
V. Conclusion
The mechanisms of the two subtypes that were dis criminated by ;3-chloroethylamines, PrBCM or CEC were investigated. There are two subtypes of M3-cholinocep tors, PrBCM-sensitive and -resistant. The full agonists contract the intestinal smooth muscle through the inter action of these two subtypes, while the partial agonists produce the contraction through the activation of the PrBCM-sensitive ones. PrBCM can differentiate between the two mechanisms in the presence of GTP, but in its absence, PrBCM cannot distinguish the two. In other words, one mechanism is PrBCM-sensitive, being opera tive irrespective of the presence or absence of GTP, and the other is PrBCM-resistant, being operative only when GTP is present. One reason for this may be that the ben zilylcholine moiety in PrBCM discriminates the two sub types. The affinity of benactyzine for the PrBCM-sensi tive receptor is about 3 times higher than that for the PrBCM-resistant one. These results lead to the following possibilities: PrBCM, which contains a benzilylcholine moiety in its structure has higher affinity to PrBCM-sen sitive receptors than to PrBCM-resistant receptors and is able to bind covalently with the former but not with the latter. The conformation of PrBCM-resistant receptors in the presence of GTP may be suitable for interaction with aziridinium ion but not for binding it covalently.
On the other hand, the rabbit thoracic aorta contains the a1B-subtype in addition to the a1A-subtype. The full agonist induces contraction through both alA and aiB subtypes, and the partial agonist induces contraction through only the alA-subtype. GTP may convert alB adrenoceptors to a conformation suitable for interaction with CEC and then bind covalently with them. Thus, CEC is able to recognize these two distinct subtypes of al-adrenoceptors only when GTP is present. Aziridinium ion is believed to interact with anionic groups in alB adrenoceptors to bind covalently. After interactions of aziridinium ion with alA and alB-adrenoceptors, the ion binds covalently with a1B-receptors but not with alA receptors.
Although r3-adrenoceptor mechanisms in guinea pig taenia caecum were not discussed in this review, ~-adrenoceptors also have two different types of binding sites, high and low-affinity sites, which could be discriminated by some partial agonists. The competitive antagonistic effect of the partial agonist is due to its abil ity to compete with the full agonist for the high-affinity site, while the partial agonist interacts with the low-affin ity site to induce the ~-adrenergic effect (86-89).
5-Chloroethylamine-sensitive and -resistant receptors may be coupled to different signal transduction mecha nisms. The receptor stimulations through alA-adreno ceptor and PrBCM-sensitive M3-cholinoceptor subtypes mainly activate the MLC-phosphorylation-independent pathway mediated through PKC and low molecular weight GTP-binding protein at low concentration of in tracellular Ca 2+ and produce efficiently sustained smooth muscle contraction, whereas the stimulations through a1B-adrenoceptor and PrBCM-resistant M3-cholinoceptor subtypes activate the MLC-phosphorylation-dependent pathway directly related to Ca 2+/calmodulin (Fig. 16 ).
